Available Until 4/22/2024
VIEW CART

JAK Inhibitors and the Changing Landscape of Atopic Dermatitis and Alopecia Areata Management

Content Release Date: 2/8/2023
Expiration Date: 4/22/2024
Activity Type: Application-based
CE Credits: up to 2.5 contact hours (0.25 CEUs)
Activity Fee:  Free

Activity Overview

This course consists of four activities (see table below) and provides up to 2.5 hours of continuing pharmacy education credit.

Part 1: 

JAK Inhibitors and the Changing Landscape of Atopic Dermatitis and Alopecia Areata Management*  

This case-based educational activity will include an overview of atopic dermatitis and alopecia areata, the pathophysiology, and the impact of each disease on patient quality of life, including comorbidities and associated health costs. New and emerging therapies will be discussed, including JAK inhibitors, to help pharmacists identify appropriate patient selection for these agents. Faculty will provide pearls to assist pharmacists caring for patients with AD and AA. 

 

Part 2: 
Ask the Experts: Atopic Dermatitis and Alopecia Areata Treatment: Beyond the Basics**

Following the 2022 presentation, “JAK Inhibitors and the Changing Landscape of Atopic Dermatitis and Alopecia Areata Management,” this ASHP webinar delves further into the specific nuances of treating the disease states of atopic dermatitis (AD) and alopecia areata (AA). Specifically, treatment of AD and AA in special patient populations, such as pediatrics and pregnancy, is addressed. In addition, faculty provides recommendations that learners can apply to challenging management scenarios of patients with AD and AA. 

Engaging the Experts Podcasts:

Podcast 1: Updates in the Management of Alopecia Areata

Podcast 2: Updates in the Management of Atopic Dermatitis
CE Credits: 1.5 hours CE Credits: 1.00 hours CE Credits: none

*Please note, this activity was presented live on December 6, 2022 as part of the ASHP 2022 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study.

**Please note, this activity was presented as a live webinar on March 22, 2023. You can only claim credit once for this activity; live or home study.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity was planned to meet the educational needs of pharmacists involved in the care of patients with atopic dermatitis and alopecia areata. 

After participating in this CPE activity, learners should be able to:

JAK Inhibitors and the Changing Landscape of Atopic Dermatitis and Alopecia Areata Management

ACPE Number: 0204-0000-22-419-H01-P

  • Discuss the impact of atopic dermatitis (AD) and alopecia areata (AA) on quality of life, comorbidities, and associated health costs.
  • Analyze safety and efficacy data, novel mechanisms of action, and routes of administration of current and emerging treatments for AD and AA.
  • Design a treatment plan for a variety of atopic dermatitis and alopecia patient cases, incorporating newer evidence-based therapies.
  • Identify the role of the pharmacist in caring for patients with AD and AA. 

Atopic Dermatitis and Alopecia Areata Treatment: Beyond the Basics

ACPE Number: 0204-0000-23-420-H01-P

  • Summarize evidence-based therapies for the treatment of atopic dermatitis and alopecia areata in pediatric patients, including newer therapies with novel mechanisms of action.
  • Apply counseling pearls when interacting with patients treated with biologic therapies and JAK inhibitors.
  • Design a treatment plan for challenging cases of patients with atopic dermatitis and alopecia areata, including patients with serious adverse effects or financial limitations. 

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, Pennsylvania 





Dr. Jamie McConaha, PharmD, NCTTP, BCACP, CDCES, is Associate Professor of Pharmacy Practice at Duquesne University School of Pharmacy, in Pittsburgh, Pennsylvania. After graduating from Duquesne, she completed a two-year academic teaching and research fellowship with the school. During her fellowship, Dr. McConaha pursued her interest in dermatology and cosmeceuticals, which led to the implementation of a new elective course at the university. Upon completion of her fellowship, Dr. McConaha joined the School of Pharmacy’s clinical faculty. Dr. McConaha continues to teach her dermatology elective, as well as other dermatologic topics within the required curriculum. She has published several peer-reviewed publications in this field. Dr. McConaha maintains a clinical practice in ambulatory care with Allegheny Health Network in Pittsburgh. 

 

Monica Dougherty, PharmD, BCACP
Clinical Pharmacy Specialist
University of Rochester Medical Center
Rochester, New York 




Monica Dougherty, PharmD, BCACP, is Clinical Pharmacy Specialist at the University of Rochester Medical Center Specialty Pharmacy in Rochester, New York. She specializes in dermatology, asthma, and allergy. Dr. Dougherty currently manages the treatment and monitoring of more than two hundred patients with atopic dermatitis, many of whom are prescribed newer therapies. Dr. Dougherty earned her Doctor of Pharmacy at University of Rhode Island College of Pharmacy. She completed her PGY1 Residency at Providence St. Vincent Medical Center, and PGY2 Ambulatory Care Residency at Providence Medical Group, both in Portland, Oregon.  

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Activities can be completed in any order. Each activity consists of audio, video and an evaluation. Learners must review all content and complete an evaluation to receive continuing education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.

Provided by ASHP
Supported by an educational grant from Pfizer Inc.